FY2025 EPS Estimates for STOK Raised by Cantor Fitzgerald

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Research analysts at Cantor Fitzgerald lifted their FY2025 earnings per share (EPS) estimates for Stoke Therapeutics in a report released on Thursday, March 20th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will earn $0.03 per share for the year, up from their previous estimate of ($2.40). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

STOK has been the topic of a number of other research reports. Chardan Capital reiterated a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 19th. HC Wainwright restated a “buy” rating and set a $47.00 price target on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, March 18th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Stoke Therapeutics currently has an average rating of “Buy” and an average target price of $23.00.

Stoke Therapeutics Price Performance

Shares of NASDAQ:STOK opened at $8.29 on Monday. The firm has a 50 day simple moving average of $9.46 and a 200 day simple moving average of $11.35. The company has a market cap of $448.31 million, a price-to-earnings ratio of -3.95 and a beta of 0.99. Stoke Therapeutics has a one year low of $6.29 and a one year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million.

Insider Activity at Stoke Therapeutics

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares of the company’s stock, valued at $1,285,353.51. The trade was a 6.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares of the company’s stock, valued at $554,550.54. This trade represents a 5.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,532 shares of company stock valued at $143,332. Corporate insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in STOK. Barclays PLC grew its stake in shares of Stoke Therapeutics by 145.3% during the third quarter. Barclays PLC now owns 79,740 shares of the company’s stock valued at $980,000 after buying an additional 47,239 shares during the last quarter. Geode Capital Management LLC boosted its position in Stoke Therapeutics by 9.7% during the 3rd quarter. Geode Capital Management LLC now owns 870,831 shares of the company’s stock valued at $10,705,000 after buying an additional 76,661 shares during the period. State Street Corp grew its holdings in Stoke Therapeutics by 8.6% in the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock worth $21,248,000 after acquiring an additional 137,145 shares during the last quarter. RTW Investments LP increased its position in shares of Stoke Therapeutics by 10.1% in the third quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock valued at $57,177,000 after acquiring an additional 427,447 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in shares of Stoke Therapeutics by 1,589.7% during the third quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock valued at $936,000 after acquiring an additional 71,647 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.